Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Targeting BKCa Channels in Migraine: Rationale and Perspectives

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Alexander Klistorner
  • Yi Chai
  • Letizia Leocani
  • Philipp Albrecht
  • Orhan Aktas
  • Helmut Butzkueven
  • Tjalf Ziemssen
  • Focke Ziemssen
  • Jette Frederiksen
  • Lei Xu
  • Diego Cadavid
  • RENEW MF-VEP Investigators
View graph of relations

BACKGROUND: Multifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials of remyelinating therapies.

OBJECTIVE: MF-VEP testing was used to study changes in visual pathways in 48% of RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants.

METHODS: This exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants in the intent-to-treat (ITT; n = 39; 72% female; mean age: 32.3 years) and per-protocol (PP; n = 31; 71% female; mean age: 32.2 years) populations in affected and fellow eye latency from fellow eye baseline latency and affected and fellow eye amplitude from their own baselines. Treatment differences were evaluated using analysis of covariance (week 24) and a mixed-effect model of repeated measures (week 32). Last observation carried forward was used to impute missing data at week 24.

RESULTS: A trend for improvement in affected eye MF-VEP latency with opicinumab versus placebo was seen in the ITT and PP populations at weeks 24 and 32. Both treatment groups in the ITT population experienced partial recovery of amplitude in the affected eye at week 32. Notably, the mean change in fellow eye amplitude at weeks 24 and 32 was - 17.57 and - 31.41 nanovolts (nV) in placebo but only - 0.59 and 1.93 nV in the opicinumab group [differences at weeks 24 and 32: 16.98 nV (p = 0.050) and 33.33 nV (p < 0.01), respectively].

CONCLUSION: Results from this substudy showed advantages of MF-VEP over FF-VEP in multicenter studies of central nervous system reparative therapies and provide novel evidence that fellow eye visual pathway amplitude loss occurs after optic neuritis but can potentially be prevented by opicinumab treatment.

REGISTRATION: identifier NCT01721161.

Original languageEnglish
JournalCNS Drugs
Issue number12
Pages (from-to)1159-1171
Number of pages13
Publication statusPublished - Dec 2018

ID: 56376752